Latham & Watkins represented Evelo Biosciences in the transaction. Evelo Biosciences, Inc. (Nasdaq: EVLO) has announced the pricing of an underwritten public offering of 4,500,000 shares…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
